OBJECTIVES: A pharmacoeconomic analysis was performed to determine the cost implications of providing rituximab (RTX, a Abstracts A235
attributable to the institution of Medicare Part D, a national prescription drug benefit program for the elderly instituted at the end of 2005 in the United States. METHODS: We implemented retrospective analyses of pharmacy claims of beneficiaries aged 67-79 years from 2005 to 2006, from a large pharmacy chain in the United States. Subjects aged 61-63 were used a control group in a differences-in-differences approach to account for trends not related to Part D. The final sample represented approximately 2.4 million unique beneficiaries aged 67-79. The main outcomes are: 1) Changes in proportion of total days of therapy dispensed as generics, and 2) changes in prescription utilization for each therapeutic class. RESULTS: Prescription drug use by these beneficiaries increased by 11% from 2005 to 2006. After adjustment for secular trends and other potential confounders, utilization of each therapeutic class was similar in 2005 and 2006. Small increases in drug utilization occurred for several drug classes, ranging from 0.66 pill days (0.46%) for users of nonsteroidal anti-inflammatories (NSAIDs) to 4.64 pill days (1.78%) for users of angiotensin-converting enzyme (ACE) inhibitors. Decreases occurred for anti-diabetic drugs (-2.06 pill days, -0.58%), betablockers (-1.24, -0.49%), and benzodiazepines (-5.96 pill days, -3.57%). Overall, beneficiaries were slightly less likely to fill prescriptions for generic drugs vs. brand-name drugs in 2006 compared to 2005 (OR 0.98, 95% CI 0.97-0.98). CONCLU-SION: Small increases in prescription drug utilization occurred across numerous drug classes for these Medicare seniors following the implementation of the Medicare Part D Prescription Benefit, while overall market share by drug class did not change significantly. Further analyses are needed to explore the degree to which these changes reflect moral hazard versus beneficial expansions of coverage.
HP4 PROMOTING A DRUG'S HEALTH ECONOMIC ADVANTAGES IN MEDICAL JOURNAL ADVERTISING IN THE U.S.: A REVIEW OF 3,500 ADS FROM 1990-2006
Neumann PJ, Palmer JA, Timm AR Tufts-New England Medical Center, Boston, MA, USA OBJECTIVES: To quantify and characterize economic-content in pharmaceutical advertisements, and its supporting evidence, in leading American medical journals from 1990-2006. METHODS: Two researchers reviewed all pharmaceutical advertisements in three leading general medical (New England Journal of Medicine, JAMA, and Annals of Internal Medicine) and specialty journals (Circulation, Gastroenterology, Neurology) in three specified months each year for 2000 through 2006. Using a standardized data collection form, we investigated economic claims (e.g., ads using the words "value", "price", "savings", "hospitalization," etc.), as well as the supporting evidence. This work builds upon our previous research of economic claims from 1990-1999, adding new data and content. RESULTS: We reviewed 3,516 pharmaceutical advertisements (2,144 from 1990-1999 and 1372 from 2000-2006) . Economic content occurred in 11.1% of ads in the 1990s, and 7.6% of ads in 2000-2006 (p = 0.0007). From 1997 to 2002, economic advertisements declined (p < 0.0001), and increased again from 2003-2006 (p = 0.0006), with a peak in 1997 at 16.2% and a nadir of 3.9% in 2002. Economic claims appeared with similar frequency in the specialty journal ads across time periods (1990s: 8.6% vs. 2000-2006: 8.5%; p = 0.91), but declined in the general medical journal ads (1990s: 13.0% vs. 2000-2006: 6.4%; p < 0.0001). The presence of supporting evidence for economic claims was similar in the 1990s and 2000s (63.7% vs. 61.5%, p = 0.70), but over time derived less from the Red Book (1990s: 38.7% vs. 2000 Book (1990s: 38.7% vs. -2006 15.6%) and average wholesale price listings (1990s: 51.1% vs. 2000-2006: 6.3%) and more from data on file (1990s: 9.5% vs. 2000-2006: 29.7%) and published studies (1990s: 6.6% vs. 2000-2006: 23.4%) . From 2000-06, a small number of ads mentioned patient compliance (2.6%) or persistence (2.0%). CONCLUSION: Drug companies continue to promote health economic messages in medical journal advertisements. Mention of supporting evidence underlying economic claims has not changed over time, though more ads reference published studies.
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IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
Tang B 1 , Rahman MI 1 , Stephenson JJ 2 , Quimbo RA 2 , Thompson HC 1 , Naim A 1 , Dabbous O 1 1 Centocor, Inc, Horsham, PA, USA, 2 HealthCore Inc, Wilmington, DE, USA OBJECTIVES: To evaluate the impact of anti-tumor necrosis factor (anti-TNF) therapy on real world health care resource utilization in patients with immune-mediated inflammatory diseases (IMIDs). METHODS: Three groups of patients were identified using claims data from Blue Cross Blue Shield health plans: IMID (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis or ulcerative colitis) patients receiving anti-TNF therapy between January 1, 2003 and June 30, 2005 (Group 1); IMID controls without anti-TNF therapy (Group 2); and non-IMID controls (Group 3). The groups were matched for gender, age and geographic region in a 3:1 ratio. All patients had > = 6 months continuous plan enrollment before and > = 12 months after the index date. Health care resource utilizations per patient per month (PPPM) were calculated for the 6-month pre-and 12-month post-index periods. Differences from baseline were compared among three groups. RESULTS: After matching, 27,006 patients (3,970 Group 1; 11,718 Group 2; and 11,318 Group 3) were analyzed. Of these, 61% were female and the average age was 46 years. Group 1 had higher pre-index PPPM resource utilization for all categories than the 2 control groups. However, compared with pre-index utilization, all postindex resource utilization categories, except emergency room visits, showed a significant decrease for Group 1 that was not consistently observed for controls. Inpatient admissions were reduced in Group 1 (-16.28%), versus no change in Group 2, and +4.17% for Group 3. Physician visits were reduced in Group 1 (-5.11%) versus +2.73% in Group 2, and +6.24% for Group 3. Non-anti-TNF prescriptions were reduced in Group 1 (-6.70%) versus +6.75% in Group 2, and +8.02% for Group 3. CONCLUSION: Anti-TNF therapy appears to be associated with a decrease in health care resource utilization. Additional analyses to determine the effectiveness of anti-TNF therapies in patients with IMIDs through clinical, economic, and humanistic assessments are recommended.
